Advertisement
UK markets closed

  • NIKKEI 225

    38,460.08
    +907.92 (+2.42%)
     

  • HANG SENG

    17,201.27
    +372.34 (+2.21%)
     

  • CRUDE OIL

    82.79
    -0.02 (-0.02%)
     

  • GOLD FUTURES

    2,329.20
    -9.20 (-0.39%)
     

  • DOW

    38,460.92
    -42.77 (-0.11%)
     

  • Bitcoin GBP

    51,410.14
    -1,812.82 (-3.41%)
     

  • CMC Crypto 200

    1,386.52
    -37.58 (-2.64%)
     

  • NASDAQ Composite

    15,712.75
    +16.11 (+0.10%)
     

  • UK FTSE All Share

    4,374.06
    -4.69 (-0.11%)
     
Money:

The five essential pieces of financial paperwork you must never lose

Mislaying key documents can cause real headaches, so it’s worth tracking down these most commonly-lost bits of paperwork

Vaccitech to Present at Upcoming September Investors Conferences

Vaccitech plc
·2-min read
Vaccitech plc
Vaccitech plc

OXFORD, United Kingdom, Sept. 07, 2022 (GLOBE NEWSWIRE) -- Vaccitech plc (NASDAQ: VACC), a clinical-stage biopharmaceutical company engaged in the discovery and development of novel immunotherapeutics and vaccines, today announced that the Company’s Chief Executive Officer, Bill Enright, and Chief Financial Officer, Georgy Egorov, will be participating in the following investment conferences in September.

Event:

Morgan Stanley 20th Annual Healthcare Conference 2022, New York City

Date:

Monday, September 12 – Wednesday, September 14

Presentation:

Fireside Chat

Time:

1:40 – 2:10 p.m. EDT on Monday, September 12

 

 

Event:

H.C. Wainwright 24th Annual Global Investment Conference, New York City

Date:

Monday, September 12 – Wednesday, September 14

Presentation:

Company Overview

Time:

10:30 a.m. EDT on Wednesday, September 14

Webcast:

Events section of the Vaccitech website

Alongside the events listed above, the Company will participate in 1x1 investor meetings that can be booked with the relevant bank representatives or directly with the Company. 

ADVERTISEMENT

About Vaccitech plc
Vaccitech (“the Company”) is a clinical-stage biopharmaceutical company engaged in the discovery and development primarily of novel immunotherapies for the treatment of chronic infectious diseases, cancer, autoimmunity and diseases where the T cell arm of the immune system is believed to play an important role. The company’s proprietary platforms include modified simian adenoviral vectors (ChAdOx1 and ChAdOx2), other viral vectors including the well-validated Modified Vaccinia Ankara (MVA) and synthetic nano-particle technologies (SNAPvax™ and Syntholytic™). The combination of different technologies in a mix and match approach (heterologous prime-boost) consistently generates significantly higher magnitudes of T cells compared with other technologies and approaches. The company has a broad pipeline of both clinical and preclinical stage therapeutic programs to treat solid tumors, chronic viral infections, as well as a few prophylactic viral vaccine programs. Vaccitech co-invented a COVID-19 vaccine with the University of Oxford, now approved for use in many territories and exclusively licensed worldwide to AstraZeneca through Oxford University Innovation, or OUI. Vaccitech is entitled to receive a share of all milestones and royalty income received by OUI from AstraZeneca.

Vaccitech Media contacts:
Katja Stout, Scius Communications (EU)
Direct: +44 (0) 7789435990
Email: katja@sciuscommunications.com

Katie Larch / Robert Flamm, Ph.D., Burns McClellan, Inc. (U.S.)
Email: klarch@burnsmc.com / rflamm@burnsmc.com

Georgy Egorov, CFO, Vaccitech
Email: IR@vaccitech.co.uk